Payment overview · 2025
General Payments
$1,398.10
45 reported records · 17 companies
Healthcare provider profile · identity verified
Bruce Torkan, M.D.
Allopathic & Osteopathic Physicians|General Practice · LOS ANGELES, CA · NPI 1699770321
Verified facts
What the public records show
CMS Open Payments records show Bruce Torkan, M.D. received $1,398.10 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $304.96 | 21.8% | 6 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $179.58 | 12.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $162.67 | 11.6% | 12 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $155.95 | 11.2% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $147.07 | 10.5% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $90.03 | 6.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.76 | 6.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.18 | 3.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.03 | 2.4% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $31.91 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.07 | 2.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.79 | 1.9% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $24.74 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.54 | 1.5% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.53 | 1.2% | 1 | 2025 |
| Verrica Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.67 | 1.2% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.62 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,398.10 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $239.81 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $179.58 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $162.67 | 12 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $155.95 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $128.09 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $110.81 | 9 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $90.03 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $58.39 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $53.18 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $53.18 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.67 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.03 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| YCANTH Normalized: ycanth |
Drug | Verrica Pharmaceuticals Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 111 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 25 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
111 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 697 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 547 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 531 | 99 |
| Misoprostol | Misoprostol | 503 | 114 |
| Gabapentin | Gabapentin | 421 | 87 |
| Metformin Hcl | Metformin Hcl | 405 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 395 | 79 |
| Ibuprofen | Ibuprofen | 367 | 129 |
| Celecoxib | Celecoxib | 308 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 57 |
| Omeprazole | Omeprazole | 283 | 59 |
| Atenolol | Atenolol | 269 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 265 | 85 |
| Furosemide | Furosemide | 250 | 55 |
| Potassium Chloride | Potassium Chloride | 245 | 55 |
| Azithromycin | Azithromycin | 231 | 132 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 220 | 54 |
| Benazepril Hcl | Benazepril Hcl | 211 | 38 |
| Trazodone Hcl | Trazodone Hcl | 196 | 50 |
| Losartan Potassium | Losartan Potassium | 188 | 35 |
| Lansoprazole | Lansoprazole | 185 | 49 |
| Glipizide | Glipizide | 154 | 28 |
| Single Use Swab | Alcohol Antiseptic Pads | 154 | 34 |
| Finasteride | Finasteride | 153 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 26 |
| Naproxen | Naproxen | 135 | 28 |
| Alendronate Sodium | Alendronate Sodium | 134 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 129 | 58 |
| Nitroglycerin | Nitroglycerin | 124 | 27 |
| Lisinopril | Lisinopril | 115 | 21 |
| Pregabalin | Pregabalin | 112 | 32 |
| Gemtesa | Vibegron | 111 | 37 |
| Simvastatin | Simvastatin | 109 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 21 |
| Meclizine Hcl | Meclizine Hcl | 98 | 38 |
| Januvia | Sitagliptin Phosphate | 90 | 20 |
| Jardiance | Empagliflozin | 86 | 12 |
| Enalapril Maleate | Enalapril Maleate | 83 | 21 |
| Albuterol Sulfate | Albuterol Sulfate | 82 | 16 |
| Donepezil Hcl | Donepezil Hcl | 82 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 80 | 17 |
| Ezetimibe | Ezetimibe | 76 | 17 |
| Famotidine | Famotidine | 75 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 74 | 14 |
| Clonidine Hcl | Clonidine Hcl | 74 | 16 |
| Carvedilol | Carvedilol | 70 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 12 |
| Vascepa | Icosapent Ethyl | 69 | 18 |
| Memantine Hcl | Memantine Hcl | 63 | 15 |
| Folic Acid | Folic Acid | 60 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 60 | suppressed |
| Procto-Med Hc | Hydrocortisone | 59 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 52 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 51 | 12 |
| Risedronate Sodium | Risedronate Sodium | 50 | suppressed |
| Glimepiride | Glimepiride | 48 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 14 |
| Hydrocortisone | Hydrocortisone | 42 | 20 |
| Meloxicam | Meloxicam | 42 | 24 |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Niacin Er | Niacin | 40 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 40 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Ondansetron Odt | Ondansetron | 36 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 13 |
| Eliquis | Apixaban | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 28 |
| Ketoconazole | Ketoconazole | 30 | 14 |
| Pentoxifylline | Pentoxifylline | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 23 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | 19 |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | 12 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 22 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 22 | 18 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 12 |
| Allopurinol | Allopurinol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Terconazole | Terconazole | 19 | 14 |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Neomycin-Polymyxin-Gramicidin | Neomycin/Polymyxn B/Gramicidin | 15 | 14 |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,398.10 · 45 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, BEXSERO, BEYFORTUS, BREZTRI, Brinsupri, CAPVAXIVE, CREON, Doc Band, ELIQUIS, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, JOURNAVX, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, REZDIFFRA, TRELEGY ELLIPTA, YCANTH, ZEPBOUND, ZTLido | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error